Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 08 04:00PM ET
4.71
Dollar change
+0.13
Percentage change
2.84
%
IndexRUT P/E- EPS (ttm)-3.06 Insider Own35.41% Shs Outstand97.87M Perf Week-7.47%
Market Cap470.11M Forward P/E- EPS next Y-2.10 Insider Trans-0.00% Shs Float64.46M Perf Month-0.21%
Income-299.80M PEG- EPS next Q-0.80 Inst Own77.39% Short Float9.45% Perf Quarter-8.19%
Sales0.00M P/S- EPS this Y45.60% Inst Trans5.58% Short Ratio5.46 Perf Half Y-20.84%
Book/sh5.71 P/B0.83 EPS next Y28.97% ROA-40.33% Short Interest6.09M Perf Year-53.46%
Cash/sh6.36 P/C0.74 EPS next 5Y- ROE-43.79% 52W Range3.36 - 10.70 Perf YTD-36.86%
Dividend Est.- P/FCF- EPS past 5Y- ROI-52.66% 52W High-56.00% Beta2.30
Dividend TTM- Quick Ratio7.86 Sales past 5Y0.00% Gross Margin- 52W Low40.18% ATR (14)0.38
Dividend Ex-Date- Current Ratio7.86 EPS Y/Y TTM- Oper. Margin0.00% RSI (14)46.63 Volatility7.62% 7.86%
Employees130 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.86 Target Price11.40
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-222.51% Payout- Rel Volume0.22 Prev Close4.58
Sales Surprise- EPS Surprise-10.26% Sales Q/Q- EarningsAug 13 AMC Avg Volume1.12M Price4.71
SMA20-3.29% SMA50-2.96% SMA200-19.03% Trades Volume244,984 Change2.84%
Date Action Analyst Rating Change Price Target Change
Aug-14-24Downgrade H.C. Wainwright Buy → Neutral $18 → $6
Jul-08-24Upgrade Wells Fargo Equal Weight → Overweight $13
Dec-13-23Initiated Wells Fargo Equal Weight $11
Dec-08-23Initiated Citigroup Neutral $8
Sep-13-23Downgrade Morgan Stanley Overweight → Equal-Weight $19
Sep-05-23Initiated H.C. Wainwright Buy $44
May-30-23Initiated TD Cowen Outperform
May-30-23Initiated Piper Sandler Overweight $68
May-30-23Initiated Morgan Stanley Overweight
May-30-23Initiated Jefferies Buy $31
Sep-19-24 07:00AM
Sep-12-24 01:30AM
Sep-10-24 07:00AM
Aug-22-24 07:00AM
Aug-13-24 04:00PM
03:37AM Loading…
03:37AM
Aug-06-24 04:30PM
Jun-05-24 07:00AM
May-29-24 07:00AM
May-15-24 11:54AM
May-09-24 08:01AM
08:00AM
Apr-29-24 04:05PM
Mar-28-24 10:53PM
04:05PM
04:01PM Loading…
Mar-27-24 04:01PM
Mar-21-24 11:12AM
Mar-20-24 07:00AM
12:39AM
Mar-11-24 10:04AM
08:02AM
08:00AM
Feb-15-24 04:05PM
Jan-10-24 11:30AM
Jan-04-24 09:56AM
Jan-01-24 09:35AM
Dec-27-23 10:45AM
Dec-20-23 04:30PM
Dec-19-23 12:13AM
Dec-18-23 04:14PM
09:25PM Loading…
Dec-12-23 09:25PM
Dec-11-23 09:35AM
Dec-04-23 03:00PM
08:00AM
Nov-30-23 04:30PM
Nov-28-23 05:55PM
01:44PM
07:24AM
Nov-27-23 09:09PM
04:30PM
Nov-20-23 11:01AM
Nov-16-23 06:42PM
04:11PM
Nov-07-23 05:11PM
04:05PM
Nov-06-23 07:00AM
Oct-31-23 04:30PM
Oct-18-23 09:00PM
Oct-03-23 07:00AM
Sep-15-23 05:39PM
Sep-11-23 04:05PM
Sep-06-23 07:00AM
Aug-15-23 07:22PM
Aug-14-23 04:05PM
Aug-07-23 04:30PM
Jul-18-23 07:00AM
Jun-15-23 04:05PM
May-09-23 04:10PM
May-05-23 07:08PM
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Becker Daniel J.DirectorJul 17 '24Sale6.86172,999Jul 19 06:18 PM
Lin Shao-LeeChief Executive OfficerApr 01 '24Sale6.639,96166,0241,577,374Apr 03 06:18 PM
Lin Shao-LeeChief Executive OfficerFeb 20 '24Sale7.6015,701119,4031,587,335Feb 22 07:04 PM
Lin Shao-LeeChief Executive OfficerJan 02 '24Sale7.4110,69179,1881,603,036Jan 04 06:09 PM